The adjuvant AlhydroGel elicits higher antibody titres than AddaVax when combined with HIV-1 subtype C gp140 from CAP256.

MLA

van Diepen, Michiel T., et al. “The Adjuvant AlhydroGel Elicits Higher Antibody Titres than AddaVax When Combined with HIV-1 Subtype C Gp140 from CAP256.” PLoS ONE, vol. 13, no. 12, Dec. 2018, pp. 1–15. EBSCOhost, https://doi.org/10.1371/journal.pone.0208310.

APA

van Diepen, M. T., Chapman, R., Moore, P. L., Margolin, E., Hermanus, T., Morris, L., Ximba, P., Rybicki, E. P., & Williamson, A.-L. (2018). The adjuvant AlhydroGel elicits higher antibody titres than AddaVax when combined with HIV-1 subtype C gp140 from CAP256. PLoS ONE, 13(12), 1–15. https://doi.org/10.1371/journal.pone.0208310

Chicago

van Diepen, Michiel T., Rosamund Chapman, Penny L. Moore, Emmanuel Margolin, Tandile Hermanus, Lynn Morris, Phindile Ximba, Edward P. Rybicki, and Anna-Lise Williamson. 2018. “The Adjuvant AlhydroGel Elicits Higher Antibody Titres than AddaVax When Combined with HIV-1 Subtype C Gp140 from CAP256.” PLoS ONE 13 (12): 1–15. doi:10.1371/journal.pone.0208310.